Holen Sie sich die Stockscreener-App
5.315
2.41%
0.125
Schlusskurs vom Vortag:
$5.19
Offen:
$5.24
24-Stunden-Volumen:
27,060
Relative Volume:
0.12
Marktkapitalisierung:
$77.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.71M
KGV:
-1.2472
EPS:
-4.2615
Netto-Cashflow:
$-19.77M
1W Leistung:
+3.20%
1M Leistung:
-0.47%
6M Leistung:
-22.41%
1J Leistung:
+37.69%
1-Tages-Spanne:
$5.16
$5.355
1-Wochen-Bereich:
$5.02
$5.4979
52-Wochen-Spanne:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.315 | 75.47M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
CING Q2 2026 Earnings: Narrower Loss Delivers 29.4% EPS SurpriseRevenue Report - vinanet.vn
Cingulate Inc. Warrants (CINGW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cingulate Inc. Warrants (CINGW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - The Globe and Mail
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionFinancial Data - dars.gov.et
Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings - MarketBeat
Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00 - MarketBeat
CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52 - Bitget
Cingulate (CING) Results at a Glance: The EPS Result Is Below Expectation in Latest Trading; Market Reaction: The Market Price Moves 1.35% Higher in the Current UpdateCFO Commentary Report - dars.gov.et
Cingulate (CINGW) Levels: Finishes 26.88% Up at $0.01 at the Close; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseValue Area Low - vinanet.vn
Cingulate (CING) Quarterly Results: EPS Comes in Below Forecast; Closing Move: Shares Close 1.73% Higher in Latest TradingSurprise Factor Analysis - vinanet.vn
CING: Second Quarter Results - Yahoo Finance
Cingulate (CING) Results Breakdown: EPS Comes in Below Forecast at the Close; Market Read: The Share Price Sheds 0.19% in the Latest SessionEarnings Revision Upgrade - vinanet.vn
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - inkl
CING Q1 2026 Earnings: Wider-Than-Expected Loss of -$0.95 Per Share as Clinical-Stage Costs Persist - vinanet.vn
Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results - MarketBeat
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August - Investing.com Nigeria
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Canada
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com Nigeria
Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary - TradingView
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash - Quiver Quantitative
Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter - TradingView
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - marketscreener.com
Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cingulate Inc. Warrants (CINGW) Rise 9.72% to $0.01 as Support and Resistance AlignSmall Cap Breakouts - dars.gov.et
Cingulate publishes pharmacokinetic study on ADHD drug candidate - Investing.com
Cingulate publishes pharmacokinetic study on ADHD drug candidate By Investing.com - Investing.com Australia
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile - GlobeNewswire
CING Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Cingulate (CING) Expected to Announce Earnings on Tuesday - MarketBeat
CING Q1 2026 Earnings: Wider-than-Expected Loss of -$0.95 per Share Highlights Clinical-Stage Cost PressuresLong-Term Guidance - vinanet.vn
Cingulate Inc. Revenue Breakdown – BOATS:CINGW - TradingView
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CING) Stock News Today - TradingKey
CING Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Funding NeedsAnnual Earnings Summary - Vinanet
Cingulate Inc. Warrants (CINGW) Fall 7.14% to $0.01 as Price Compresses at Key SupportMonthly Profile - vinanet.vn
Cingulate publishes phase 3 ADHD drug trial results in journal By Investing.com - Investing.com Nigeria
Cingulate Inc. Warrants (CINGW) Hold at $0.01 After 8.33% Gain as Speculative Interest PersistsMid Cap Momentum - dars.gov.et
Cingulate Inc. Warrants (CINGW) Edge Lower as Trading Remains Tight Near $0.02Island Reversal - vinanet.vn
Cingulate Inc (CING) Cash Flow - TradingKey
Cingulate Inc (CING) Income Statement - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):